Fangsheng Ruixin is an intensive chain service platform jointly built by Fangsheng Pharmaceutical and a national growth chain through the “equity cooperation + industrial and commercial cooperation” model. Ruixin will gradually hold 200-300 drug approvals and declare 50-100 health care products. products, acquired 2-3 traditional Chinese medicine decoction pieces factories, and directly supplied them to the chain of shareholders at the factory price, reducing the procurement cost to the bottom line. Recently completed a new round of strategic financing, the investor is Shangshan Jinshi.
This article is reproduced from: https://www.itjuzi.com/investevent/13233745
This site is for inclusion only, and the copyright belongs to the original author.